bioRxiv Reports Novel AR Molecular Glue Degrader GZL626 Inhibits Prostate Cancer Cell Proliferation, Effective Against AR-V7

bioRxiv USA

Overview

A preprint published on bioRxiv reports a novel androgen receptor (AR) molecular glue degrader, GZL626. GZL626 was shown to induce proteasome-dependent degradation of both full-length AR and the AR splicing variant AR-V7, a key driver of anti-androgen therapy resistance, via bivalent engagement with an E3 ligase and the AR N-terminal domain. This effectively inhibits the proliferation of AR-positive prostate cancer cells, promising a new therapeutic strategy for treatment-resistant prostate cancer.

In Depth

Key Findings

A new study, released as a preprint on bioRxiv, reports the discovery of GZL626, a novel androgen receptor (AR) molecular glue degrader. GZL626 demonstrates the remarkable ability to induce the proteasome-dependent degradation of both full-length AR and the AR splicing variant AR-V7, which is a significant driver of resistance to current anti-androgen therapies. This molecular glue degrader effectively inhibits the proliferation of AR-positive prostate cancer cells, indicating substantial potential as a new therapeutic strategy, particularly for treatment-resistant prostate cancer.

Technical and Theoretical Details

Androgen receptor (AR) remains a central therapeutic target in prostate cancer. However, despite advancements in novel anti-androgen therapies, many patients ultimately progress to castration-resistant prostate cancer (CRPC). A primary mechanism of CRPC involves AR hyperactivity or the expression of AR splicing variants, such as AR-V7, which lack the ligand-binding domain but remain functionally active and contribute to therapeutic resistance.

GZL626 is a small molecule classified as a molecular glue. It functions by inducing proximity between a specific E3 ubiquitin ligase and the AR. The study shows that GZL626 achieves this through a bivalent engagement strategy, binding to both the N-terminal domain (NTD) of AR and the RNF213–UBE2J2 E3 ligase complex. This bivalent interaction facilitates the formation of a stable complex, promoting the ubiquitination of AR. Ubiquitinated AR is then recognized and efficiently degraded by the cellular proteasome system.

The research confirmed several key effects of GZL626:

• Degradation of full-length AR and AR-V7: GZL626 effectively degrades both full-length AR and AR-V7, which is particularly significant as many current AR-targeted drugs show limited efficacy against AR-V7-expressing CRPC.
• Inhibition of prostate cancer cell proliferation: Experiments using AR-positive prostate cancer cell lines demonstrated that GZL626 potently suppresses cell proliferation.

This degradation-inducing mechanism, via bivalent engagement, offers a potentially more potent and durable anti-cancer effect compared to traditional AR inhibitors that merely block functional domains but do not remove the protein itself from the cell.

Background and Industry Context

Castration-resistant prostate cancer represents a highly challenging disease to treat, with an urgent need for new therapeutic options. The expression of AR-V7, in particular, is associated with resistance to existing AR-targeted agents like enzalutamide and abiraterone, leaving limited effective choices for these patients.

Molecular glue degraders are among the most innovative modalities in the field of Targeted Protein Degradation (TPD). Similar to PROTACs, molecular glues hold the promise of targeting ‘undruggable’ proteins or those that exhibit resistance to existing drugs. The development of GZL626 signifies the potential of TPD technologies to overcome the recalcitrance of prostate cancer and establish new therapeutic paradigms.

Strategic Significance and Outlook

Novel AR molecular glue degraders like GZL626 offer significant hope for patients with castration-resistant prostate cancer, especially those who are AR-V7 positive. While this research is currently in the preprint stage, further validation in animal models and subsequent transition to clinical trials are anticipated. If successful, GZL626 could become a breakthrough drug that overcomes resistance to existing anti-androgen therapies and fundamentally changes the prostate cancer treatment landscape. This achievement will also likely accelerate the development of molecular glue degraders for other diseases.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

• Your email and selected fields are used only to deliver the newsletter.
• We never share your information with third parties.
• You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Agree & Continue ▶

Takes about a minute · Unsubscribe anytime